Bifidobacterium Longum Subsp. Infantis BI03 Strain for Alleviating Parkinson's Disease
Summary
The USPTO has published application US20260108568A1 for a Bifidobacterium longum subsp. infantis BI03 strain (CGMCC No. 24473, deposited March 7, 2022) for alleviating Parkinson's disease. The application claims the strain can alleviate Parkinson's-related dyskinesia and corticosterone elevation, weaken associated neuroinflammation, promote glutathione, and reduce brain oxidative stress damage. Inventors include Shuguang FANG, Yao DONG, Yixuan FAN, Zhonghui GAI, and Jianguo ZHU; the application was filed May 27, 2024.
“The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
The USPTO has published application US20260108568A1 disclosing a Bifidobacterium longum subsp. infantis BI03 strain deposited as CGMCC No. 24473, claiming therapeutic use for alleviating Parkinson's disease symptoms including dyskinesia, corticosterone elevation, neuroinflammation, and brain oxidative stress damage.
Pharmaceutical and biotechnology companies developing microbiome-based therapeutics or competing Parkinson's disease treatments should monitor this application as it proceeds through examination. Freedom-to-operate analyses for probiotic or bacterial strain products targeting neurological indications may be affected once the patent publishes. No compliance obligations arise from the publication itself.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS FOR ALLEVIATING PARKINSON'S DISEASE AND USE THEREOF
Application US20260108568A1 Kind: A1 Apr 23, 2026
Inventors
Shuguang FANG, Yao DONG, Yixuan FAN, Zhonghui GAI, Jianguo ZHU
Abstract
Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No. 24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.
CPC Classifications
A61K 35/745 A61P 25/16 C12N 1/205 A61K 2035/115 C12R 2001/01
Filing Date
2024-05-27
Application No.
18995578
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.